Post-reversible cerebral vasoconstriction syndrome headache.
Chronic headache
Prognosis
Prospective
Thunderclap headache
Vasospasm
Journal
The journal of headache and pain
ISSN: 1129-2377
Titre abrégé: J Headache Pain
Pays: England
ID NLM: 100940562
Informations de publication
Date de publication:
25 Mar 2021
25 Mar 2021
Historique:
received:
06
01
2021
accepted:
12
03
2021
entrez:
26
3
2021
pubmed:
27
3
2021
medline:
30
3
2021
Statut:
epublish
Résumé
Chronic headache may persist after the remission of reversible cerebral vasoconstriction syndrome (RCVS) in some patients. We aimed to investigate the prevalence, characteristics, risk factors, and the impact of post-RCVS headache. We prospectively recruited patients with RCVS and collected their baseline demographics, including psychological distress measured by Hospital Anxiety and Depression scale. We evaluated whether the patients developed post-RCVS headache 3 months after RCVS onset. The manifestations of post-RCVS headache and headache-related disability measured by Migraine Disability Assessment (MIDAS) scores were recorded. From 2017 to 2019, 134 patients with RCVS were recruited, of whom, 123 finished follow-up interviews (response rate 91.8%). Sixty (48.8%) patients had post-RCVS headache. Migrainous features were common in post-RCVS headache. Post-RCVS headache caused moderate-to-severe headache-related disability (MIDAS score > 10) in seven (11.7%) patients. Higher anxiety level (odds ratio 1.21, p = 0.009) and a history of migraine (odds ratio 2.59, p = 0.049) are associated with post-RCVS headache. Survival analysis estimated that 50% post-RCVS headache would recover in 389 days (95% confidence interval: 198.5-579) after disease onset. Post-RCVS headache is common, affecting half of patients and being disabling in one-tenth. Higher anxiety level and migraine history are risk factors. Half of the patients with post-RCVS headache would recover in about a year.
Sections du résumé
BACKGROUND
BACKGROUND
Chronic headache may persist after the remission of reversible cerebral vasoconstriction syndrome (RCVS) in some patients. We aimed to investigate the prevalence, characteristics, risk factors, and the impact of post-RCVS headache.
METHODS
METHODS
We prospectively recruited patients with RCVS and collected their baseline demographics, including psychological distress measured by Hospital Anxiety and Depression scale. We evaluated whether the patients developed post-RCVS headache 3 months after RCVS onset. The manifestations of post-RCVS headache and headache-related disability measured by Migraine Disability Assessment (MIDAS) scores were recorded.
RESULTS
RESULTS
From 2017 to 2019, 134 patients with RCVS were recruited, of whom, 123 finished follow-up interviews (response rate 91.8%). Sixty (48.8%) patients had post-RCVS headache. Migrainous features were common in post-RCVS headache. Post-RCVS headache caused moderate-to-severe headache-related disability (MIDAS score > 10) in seven (11.7%) patients. Higher anxiety level (odds ratio 1.21, p = 0.009) and a history of migraine (odds ratio 2.59, p = 0.049) are associated with post-RCVS headache. Survival analysis estimated that 50% post-RCVS headache would recover in 389 days (95% confidence interval: 198.5-579) after disease onset.
CONCLUSIONS
CONCLUSIONS
Post-RCVS headache is common, affecting half of patients and being disabling in one-tenth. Higher anxiety level and migraine history are risk factors. Half of the patients with post-RCVS headache would recover in about a year.
Identifiants
pubmed: 33765906
doi: 10.1186/s10194-021-01223-9
pii: 10.1186/s10194-021-01223-9
pmc: PMC7992969
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
14Subventions
Organisme : Ministry of Science and Technology, Taiwan (TW)
ID : 108-2314-B-010-022-MY3
Organisme : Ministry of Science and Technology, Taiwan
ID : 108-2321-B-010-014-MY2
Organisme : Taipei Veterans General Hospital
ID : VGH-109-C-139
Références
Ann Intern Med. 2007 Jan 2;146(1):34-44
pubmed: 17200220
Cephalalgia. 2016 Apr;36(4):387-94
pubmed: 26088331
JAMA Neurol. 2018 Sep 1;75(9):1106-1113
pubmed: 29868878
NMR Biomed. 2012 May;25(5):806-12
pubmed: 22020869
J Headache Pain. 2014 Dec 02;15:82
pubmed: 25466718
Ann Neurol. 2011 Nov;70(5):838-45
pubmed: 22162064
Ann Neurol. 2010 May;67(5):648-56
pubmed: 20437562
J Headache Pain. 2013 Dec 23;14:100
pubmed: 24364890
Stroke. 2020 Feb;51(2):670-673
pubmed: 31842705
Cephalalgia. 2018 Jan;38(1):1-211
pubmed: 29368949
Neurology. 2015 Apr 14;84(15):1552-8
pubmed: 25788554
NMR Biomed. 2013 Sep;26(9):1051-8
pubmed: 23348909
J Headache Pain. 2017 Dec;18(1):29
pubmed: 28229321
Headache. 2019 May;59(5):789-794
pubmed: 30830966
J Neurosci. 2001 Dec 15;21(24):9896-903
pubmed: 11739597
Neurology. 2012 Jul 31;79(5):474-9
pubmed: 22815557
Neurology. 2008 Apr 22;70(17):1510-7
pubmed: 18354079
J Headache Pain. 2013 Nov 25;14:94
pubmed: 24274860
J Formos Med Assoc. 2006 Jul;105(7):563-8
pubmed: 16877236
PLoS One. 2012;7(12):e52927
pubmed: 23285228
J Pain. 2005 Sep;6(9):612-9
pubmed: 16139780